Earlier cancer detection, wider reimbursement and emerging-market access boost demand, while oral therapies, antimetabolites, ADCs, telehealth and online pharmacies create opportunities.Dublin, Aug.

Tetravalent death receptor 5 (DR5) agonist ozekibart (INBRX-109) + FOLFIRI in 2L+ colorectal adenocarcinoma (CRC): Preliminary results from a phase 1 study. This is an ASCO Meeting Abstract from the ...

Daraxonrasib significantly extends survival in metastatic pancreatic cancer compared to chemotherapy. Read more for key ...

Triple-negative breast cancer (TNBC) is among the most aggressive types of breast cancer, lacking estrogen, progesterone, and HER2 receptors and thus relying primarily on cytotoxic chemotherapy.

Chemotherapy-induced thrombocytopenia (CIT) is a common complication of chemotherapy that is associated with bleeding, reduced relative dose intensity, and potentially worse outcomes. No widely ...